Is a serial life sciences entrepreneur who has founded and successfully exited four companies including a structural heart start-up, a new treatment paradigm for respiratory patients and what was the largest sleep testing company in the U.S. Most recently, Mr Niland was President and CEO of Harpoon Medical, Inc. He co-founded Harpoon and successfully exited to Edwards Lifesciences in less than five years for $100M upfront (potentially $250M with milestones) with only $6.5M in dilutive capital, generating >100% IRR for investors. Prior to Harpoon, he founded Vapotherm (NYSE: VAPO) a non-invasive ventilation company that created the field of high flow nasal canula therapy for patients in respiratory distress. Vapotherm devices have been used to treat >1.5M patients since being founded in 1997 and the company recently went public on the New York Stock Exchange. Prior to Vapotherm, Mr. Niland successfully founded and exited two businesses, including National Sleep Technologies which was the largest sleep diagnostic and therapy company in the US when it was acquired by Vital Signs. Mr. Niland also holds 16 patents.
Professor and Chief of Pediatric Cardiac Surgery at the University of Maryland School of Medicine and an expert in heart failure both in children and adults. He performs over 200 cardiac surgery operations per year, has published over 100 peer-reviewed journal articles, and has a 10-member post-doctorate research laboratory funded partly through National Institute of Health grants.
Has 10 years experience in stem cells and is an expert in cardiac progenitor cell biology at the Department of Cardiac Surgery at the University of Maryland School of Medicine. She has generated progenitor cells from over 500 cardiac biopsies including neonates and adults, identified the niche of progenitor cells in right atrial appendage of neonate heart, has published over 18 peer-reviewed journal articles, and also manages a 10- members research laboratory.
Assistant Professor in the Department of Cardiac Surgery at the University of Maryland School of Medicine, holds PhD in Molecular Biology and Biotechnology and is an expert in data analysis. He co-authored (with Dr. Mishra) the study identifying secretome as the functional unit of neonatal cardiac progenitor cells, has published over 16 peer-reviewed journal articles, and currently studying cardiomyocytes regeneration after myocardial infarction.
Has a broad background in accounting, information systems, human resources, purchasing, operations and customer service. Mr. Collins and Mr. Niland have worked together for 15 years. For the last 5 years they worked together at Harpoon Medical, where Mr. Collins was the VP of Finance and Operations and for 9+ years before that at Vapotherm where he built a strong corporate foundation to support hyper growth from $1.37M in sales to a peak of $13.9M. Mark’s 25-year career includes long tenures at Emerson as a plant controller and Bowles Fluidics as a senior costs accountant.
Peter Boyd is a business development executive with a broad range of business and legal experience. Mr. Boyd worked with Mr. Niland at his last two companies, Harpoon Medical and Vapotherm. Most recently, Mr. Boyd worked with Edwards Lifesciences. He joined Edwards through the Harpoon Medical acquisition and was the Harpoon representative to a three-person post-merger integration team where he focused on European commercialization efforts and the overall commercialization strategy for the Harpoon product offering. Mr. Boyd was a member of the co-founding team at Harpoon Medical and was responsible for fundraising, business development, strategy and oversaw all legal aspects for the company. Prior to Harpoon, he was an associate at Latham & Watkins in their Silicon Valley emerging growth companies and corporate department. During his tenure at Latham, Mr. Boyd represented a wide range of early stage companies in the healthcare and technology spaces in a variety of transactions including venture financings, joint ventures, licensing transactions and M&A deals. As an attorney and entrepreneur, Mr. Boyd has participated in dozens of preferred stock and convertible debt financings totaling more than $200M. Mr. Boyd has a JD and an MBA from UVA and is an inventor on 5 issued US patents and 2 patent applications.
Pharmaceuticals executive with substantial leadership and management experience both in the academic and pharmaceutical industry settings. Directed a laboratory of up to 15 students, postdoctoral, and clinical fellows in innovative research that led to important findings published in high-impact, peer-reviewed journals. Led a variety of drug discovery teams, ranging in size from 16 to 245 colleagues, across diverse geographic locations, disciplines, and functional interfaces. Headed the delivery of CVMD strategic objectives managing a portfolio of programs in multiple therapeutic areas, driving identification and delivery of innovative new programs, in-licensing, partnering, and collaborations with academic groups, venture and non-profit research organizations, biotech and big-pharma companies.
Has a background in project management, digital solutions, marketing, and finance. For the last 8 years, Mr. Niland has advanced from starting and growing a Washington D.C. mega-dealership group’s digital marketing department to becoming the website/advertising Program Manager for the majority of the 852 Acura and Mazda dealerships in the US.